Skip to main content

Table 1 Summary of the characteristics of the studies included in the network meta-analysis

From: Respiratory support strategy in adults with acute hypoxemic respiratory failure: a systematic review and network meta-analysis

Source

Total no. of patients

Main reason for hypoxemic respiratory failure (main baseline risk factor)

Main exposure

Comparator

P/F ratio (mean)

Outcomes of interest assessed

Wysocki [27] 1995

41

Mixed AHRF (CAP 39.0%, CPE 34.1%)

NIV (n = 21)

SOT (n = 20)

207

Mortality, intubation

Antolnelli [26] 1998

64

Mixed AHRF (CPE 19%, atelectasis 25%)

NIV (n = 32)

IMV (n=32)

120

Mortality

Confalonieri [29] 1999

56

CAP

NIV (n = 28)

SOT (n = 28)

175

Mortality, intubation

Antonelli [28] 2000

40

Mixed AHRF (ARDS 37.5%, atelectasis 25%)

NIV (n = 20)

SOT (n = 20)

NA

Mortality, intubation

Delcaux [30] 2000

123

Mixed AHRF (CAP 54.5%)

NIV (n = 62)

SOT (n = 61)

144

Mortality, intubation

Martin [32] 2000

61

Mixed AHRF (COPD 38%)

NIV (n = 32)

SOT (n = 29)

199

Mortality, intubation

Hilbert [31] 2001

52

CAP in immunocompromised patients

NIV (n = 26)

SOT (n = 26)

139

Mortality, intubation

Ferrer [34] 2003

105

Mixed AHRF (CAP 32.4%, CPE 28.6%)

NIV (n = 51)

SOT (n = 54)

103

Mortality, intubation

Cosentini [33] 2010

47

CAP

NIV (n = 20)

SOT (n = 27)

248

Mortality, intubation

Squadrone [35] 2010

40

Mixed AHRF in immunocompromised patients

NIV (n = 20)

SOT (n = 20)

269

Mortality, intubation

Wermke [37] 2012

86

CAP in immunocompromised patients

NIV (n = 42)

SOT (n = 44)

270

Mortality, intubation

Zhan [38] 2012

40

ALI (immunocompromised 30%)

NIV (n = 21)

SOT (n = 19)

230

Mortality, intubation

Brambilila [36] 2014

81

CAP (immunocompromised 32%)

NIV (n = 40)

SOT (n = 41)

141

Mortality, intubation

Azevedo [39] 2015

30

CPE (43.3%), CAP (33.3%)

NIV (n=16)

HFNO (n=14)

NA

Intubation

Frat [12] 2015

310

Mixed ARF (CAP 63.5%)

NIV (n = 110)

HFNO (n = 106)

SOT (n = 94)

155

Mortality, intubation

Lamiale [40] 2015

100

Mixed AHRF in immunocompromised patients (sepsis related 50%)

HFNO (n = 52)

SOT (n = 48)

114

Intubation

Lemiale [41] 2015

374

Pneumonia in immunocompromised patients

NIV (n = 191)

SOT (n = 183)

142

Mortality, intubation

Jones [43] 2016

303

Mixed AHRF (COPD 23.9%, Pneumonia 23.8%)

HFNO (n = 165)

SOT (n = 138)

NA

Mortality, intubation

Muncharaz [42] 2017

65

Mixed AHRF (CAP 63.1%)

NIV (n = 34)

IMV (n = 31)

97

Mortality

Azoulay [25] 2018

776

Mixed AHRF in immunocompromised patients (Pneumonia 53.0%)

HFNO (n = 388)

SOT (n = 388)

132

Mortality, intubation

He [44] 2019

200

CAP

NIV (n = 102)

SOT (n = 98)

231

Mortality, intubation

Andino [45] 2020

46

Mixed AHRF (CAP 30%)

HFNO (n = 24)

SOT(n=22)

96

Mortality, intubation

AlptekÄ°noÄžlu MendÄ°l [46] 2021

100

Mixed AHRF (pneumonia 74%)

HFNO (n = 51)

SOT(n=49)

262

Mortality, intubation

Awadallah [47] 2021

52

ARDS

NIV (n = 26)

IMV (n = 26)

95

Mortality

Grieco [48] 2021

109

AHRF in COVID-19 patients

NIV (n = 54)

HFNO (n = 55)

102

Mortality, intubation

  1. AHRF acute hypoxemic respiratory failure, ALI acute lung injury, ARDS acute respiratory distress syndrome, ARF acute respiratory failure, CAP community-acquired pneumonia, COPD chronic obstructive pulmonary disease, CPE cardiopulmonary edema, HFNO high-flow nasal oxygen, IMV invasive mechanical ventilation, NA not available, NIV noninvasive ventilation, P/F ratio ratio of arterial oxygen partial pressure to fractional inspired oxygen, SOT standard oxygen therapy